Cargando…

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling

BACKGROUND: Simultaneous inhibition of multiple components of the BRAF-MEK-ERK cascade (vertical inhibition) has become a standard of care for treating BRAF-mutant melanoma. However, the molecular mechanism of how vertical inhibition synergistically suppresses intracellular ERK activity, and consequ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamis, Sara J., Kapelyukh, Yury, McLaren, Aileen, Henderson, Colin J., Roland Wolf, C., Chaplain, Mark A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608797/ https://www.ncbi.nlm.nih.gov/pubmed/34621046 http://dx.doi.org/10.1038/s41416-021-01565-w

Ejemplares similares

Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism
por: Henderson, Colin J., et al.
Publicado: (2023)

FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation
por: Gao, Chenxi, et al.
Publicado: (2023)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019)

Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA
por: Tran, Hung, et al.
Publicado: (2020)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
por: Ozkan-Dagliyan, Irem, et al.
Publicado: (2020)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

ERK1b, a 46‐kDa ERK isoform that is differentially regulated by MEK
por: Yung, Yuval, et al.
Publicado: (2022)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
por: Thomas, Kubin, et al.
Publicado: (2020)

The MEK5/ERK5 Pathway in Health and Disease
por: Paudel, Rupesh, et al.
Publicado: (2021)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
por: Chen, Brenden, et al.
Publicado: (2012)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

How to Steer and Control ERK and the ERK Signaling Cascade Exemplified by Looking at Cardiac Insufficiency
por: Breitenbach, Tim, et al.
Publicado: (2019)

Navigating the ERK1/2 MAPK Cascade
por: Martin-Vega, Ana, et al.
Publicado: (2023)

Higher polymerase activity of a human influenza virus enhances activation of the hemagglutinin-induced Raf/MEK/ERK signal cascade
por: Marjuki, Henju, et al.
Publicado: (2007)

Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma
por: Hu, Huanrong, et al.
Publicado: (2019)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Overproduction of thrombopoietin by BRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis
por: Tanaka, Hiroki, et al.
Publicado: (2019)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
por: De Paolo, Raffaella, et al.
Publicado: (2023)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
por: Cseh, Botond, et al.
Publicado: (2014)

The MEK/ERK Pathway Promotes NOTCH Signalling in Pancreatic Cancer Cells
por: Tremblay, Isabelle, et al.
Publicado: (2013)

RNA sequencing analysis to demonstrate Erk dependent and independent functions of Mek
por: Liu, Chang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8cqueabga5j0csbdgli72n1lrv